173 related articles for article (PubMed ID: 28114606)
1. A Novel Alternate Dosing of Vismodegib for Treatment of Patients With Advanced Basal Cell Carcinomas.
Becker LR; Aakhus AE; Reich HC; Lee PK
JAMA Dermatol; 2017 Apr; 153(4):321-322. PubMed ID: 28114606
[No Abstract] [Full Text] [Related]
2. Vismodegib Efficacy in Advanced Basal Cell Carcinoma Maintained with 8-Week Dose Interruptions: A Model-Based Evaluation.
Chanu P; Musib L; Wang X; Cheeti S; Girish S; Bruno R; Lu T; Reddy J; Jin JY; Caro I
J Invest Dermatol; 2021 Apr; 141(4):930-933. PubMed ID: 32976880
[No Abstract] [Full Text] [Related]
3. Effective and Tolerable Treatment of Advanced Basal Cell Carcinoma With Vismodegib Despite Renal Insufficiency.
Maul LV; Kähler KC; Hauschild A
JAMA Dermatol; 2016 Dec; 152(12):1387-1388. PubMed ID: 26720040
[No Abstract] [Full Text] [Related]
4. Vismodegib treatment in a HIV positive patient on antiretroviral therapy.
Scalvenzi M; Villani A; Mazzella C; Cappello M; Salvatores GF; Costa C
Indian J Dermatol Venereol Leprol; 2018; 84(6):758-760. PubMed ID: 30226476
[No Abstract] [Full Text] [Related]
5. Outcomes of Vismodegib for Periocular Locally Advanced Basal Cell Carcinoma From an Open-label Trial.
Ben Ishai M; Tiosano A; Fenig E; Ben Simon G; Yassur I
JAMA Ophthalmol; 2020 Jul; 138(7):749-755. PubMed ID: 32407451
[TBL] [Abstract][Full Text] [Related]
6. Concurrent Vismodegib and Radiotherapy for Recurrent, Advanced Basal Cell Carcinoma.
Pollom EL; Bui TT; Chang AL; Colevas AD; Hara WY
JAMA Dermatol; 2015 Sep; 151(9):998-1001. PubMed ID: 25874733
[TBL] [Abstract][Full Text] [Related]
7. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial.
Basset-Seguin N; Hauschild A; Grob JJ; Kunstfeld R; Dréno B; Mortier L; Ascierto PA; Licitra L; Dutriaux C; Thomas L; Jouary T; Meyer N; Guillot B; Dummer R; Fife K; Ernst DS; Williams S; Fittipaldo A; Xynos I; Hansson J
Lancet Oncol; 2015 Jun; 16(6):729-36. PubMed ID: 25981813
[TBL] [Abstract][Full Text] [Related]
8. Outcomes for Basal Cell Carcinoma Treated With Vismodegib Extended Alternate Day Dosing.
Routt E; Ratner D
Dermatol Surg; 2020 Aug; 46(8):1109-1112. PubMed ID: 31274526
[No Abstract] [Full Text] [Related]
9. Comparison of daily dosing versus Monday through Friday dosing of vismodegib for locally advanced basal cell carcinoma and basal cell nevus syndrome: A retrospective case series.
Wong C; Poblete-Lopez C; Vidimos A
J Am Acad Dermatol; 2020 Jun; 82(6):1539-1542. PubMed ID: 32092372
[No Abstract] [Full Text] [Related]
10. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial.
Dréno B; Kunstfeld R; Hauschild A; Fosko S; Zloty D; Labeille B; Grob JJ; Puig S; Gilberg F; Bergström D; Page DR; Rogers G; Schadendorf D
Lancet Oncol; 2017 Mar; 18(3):404-412. PubMed ID: 28188086
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular, and superficial) of high-risk or locally advanced basal cell carcinoma, in an open-label, prospective case series clinical trial.
Fosko SW; Chu MB; Armbrecht E; Galperin T; Potts GA; Mattox A; Kurta A; Polito K; Slutsky JB; Burkemper NM; Hurley MY
J Am Acad Dermatol; 2020 Apr; 82(4):946-954. PubMed ID: 31836564
[TBL] [Abstract][Full Text] [Related]
12. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
13. Noninvasive monitoring of basal cell carcinomas treated with systemic hedgehog inhibitors: pseudocysts as a sign of tumor regression.
Maier T; Kulichova D; Ruzicka T; Berking C
J Am Acad Dermatol; 2014 Oct; 71(4):725-30. PubMed ID: 24928708
[TBL] [Abstract][Full Text] [Related]
14. Vismodegib for the treatment of aggressive basal cell carcinoma in a patient unable to swallow pills.
Umanoff N; Sarbib K; Mulvaney M; Iorizzo L
Dermatol Surg; 2015 Mar; 41(3):433-5. PubMed ID: 25738448
[No Abstract] [Full Text] [Related]
15. Neoadjuvant Vismodegib and Mohs Micrographic Surgery for Locally Advanced Periocular Basal Cell Carcinoma.
González AR; Etchichury D; Gil ME; Del Aguila R
Ophthalmic Plast Reconstr Surg; 2019; 35(1):56-61. PubMed ID: 30444747
[TBL] [Abstract][Full Text] [Related]
16. BCC and vismodegib: can we treat and remold at the same time?
Russo F; Mancini V; Trovato E; Fimiani M; Taddeucci P
G Ital Dermatol Venereol; 2020 Feb; 155(1):119-120. PubMed ID: 29781264
[No Abstract] [Full Text] [Related]
17. Compassionate use of vismodegib and adjuvant radiotherapy in the treatment of multiple locally advanced and inoperable basal cell carcinomas and squamous cell carcinomas of the skin.
Gathings RM; Orscheln CS; Huang WW
J Am Acad Dermatol; 2014 Apr; 70(4):e88-e89. PubMed ID: 24629372
[No Abstract] [Full Text] [Related]
18. Managing adverse effects by dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor vismodegib: a single centre experience.
Woltsche N; Pichler N; Wolf I; Di Meo N; Zalaudek I
J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):e144-e145. PubMed ID: 30472793
[No Abstract] [Full Text] [Related]
19. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.
Sekulic A; Migden MR; Lewis K; Hainsworth JD; Solomon JA; Yoo S; Arron ST; Friedlander PA; Marmur E; Rudin CM; Chang AL; Dirix L; Hou J; Yue H; Hauschild A;
J Am Acad Dermatol; 2015 Jun; 72(6):1021-6.e8. PubMed ID: 25981002
[TBL] [Abstract][Full Text] [Related]
20. Systemic therapy for advanced basal cell carcinoma.
Maybury CM; Craythorne EE; Urbano TG; Mallipeddi R
Lancet Oncol; 2015 Jun; 16(6):608-10. PubMed ID: 25981816
[No Abstract] [Full Text] [Related]
[Next] [New Search]
